Bad news from FDA prompts Spero to lay off 75% of staff, drop UTI drugnews2022-05-03T14:40:12+00:00May 3rd, 2022|FierceBiotech|
After a dismal last year, Sesen Bio grasps for alternatives to stay afloatnews2022-05-03T14:18:01+00:00May 3rd, 2022|FierceBiotech|
Sierra wanted a partnership, but GSK wanted the store: How the $1.9B buyout came to benews2022-05-03T14:04:56+00:00May 3rd, 2022|FierceBiotech|
Early clinical data on psilocybin in anorexia point Compass to potential new opportunitynews2022-05-03T12:34:54+00:00May 3rd, 2022|FierceBiotech|
Dianthus to follow ‘north star’ on mission to reduce autoimmune injections with $100M fundingnews2022-05-03T12:19:22+00:00May 3rd, 2022|FierceBiotech|
Tackling toxicity, Tubulis lands $63M to advance ADC pipeline spearheaded by Adcetris rivalnews2022-05-03T07:10:53+00:00May 3rd, 2022|FierceBiotech|
As expected, FDA spikes down Axsome migraine med, but issues are ‘addressable’news2022-05-02T20:25:51+00:00May 2nd, 2022|FierceBiotech|
All Takeda wants for its billion-dollar gene therapy spending spree is functional curesnews2022-05-02T19:36:34+00:00May 2nd, 2022|FierceBiotech|
Biogen takes another dip into Scribe gene therapy collab with another disease targetnews2022-05-02T17:30:01+00:00May 2nd, 2022|FierceBiotech|
Patient Square Capital invests $300M to support ‘golden age of therapeutics’ with Enavate Sciencesnews2022-05-02T15:52:57+00:00May 2nd, 2022|FierceBiotech|
